MBX — MBX Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1776111 ·
Last close
$53.10
Market Cap
$2.64B
52W High
$72.64
52W Low
$25.11
ADV30
566,150
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -66,343,000 | -62,421,000 | 500,618,000 | 161,691,000 | 27,671,000 |
| Jun 2026 | 0 | — | -40,931,000 | -37,095,000 | 435,909,000 | 54,124,000 | 26,370,000 |
| Mar 2026 | 0 | — | -27,265,000 | -23,517,000 | 452,701,000 | 45,214,000 | 14,945,000 |
| Dec 2025 | 0 | — | -25,795,000 | -22,062,000 | 385,144,000 | 75,289,000 | 15,921,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-96,008,000
Investing CF
$-155,027,000
Financing CF
$189,806,000
CapEx
$-3,322,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.06
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-347,509,000
Inventory
—
Receivables
$3,231,000
ST Investments
$319,903,000
EBIT TTM
$-160,334,000
Pretax Income TTM
$-145,095,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -98,055,000 | -86,971,000 | 385,144,000 | 15,921,000 | 369,223,000 | -79,949,000 |
| Dec 2024 | 0 | -68,194,000 | -61,922,000 | 268,535,000 | 11,093,000 | 257,442,000 | -54,681,000 |
| Dec 2023 | 0 | -35,311,000 | -32,563,000 | 84,180,000 | 156,648,000 | -72,468,000 | -31,978,000 |
| Dec 2022 | 0 | -25,161,000 | -26,135,000 | 45,095,000 | 87,700,000 | -42,605,000 | -23,122,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-104,292,000
OpCashFlow TTM
—
Assets (Latest)
$435,909,000
Forward EPS
$-4.35
Max Pain — expiry 2026-12-18
max pain strike: $60.00 · spot: $53.42 · call oi: 2,139 · put oi: 442
Expected Move to 2026-12-18:
±$18.60
(34.82%) —
implied range
$34.82 –
$72.02
· ATM straddle on $55.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | $2.65B | $27.40 | — |
| XNCR | Xencor Inc | $2.59B | $34.50 | — |
| HCM | HUTCHMED (China) Ltd | $2.50B | $14.40 | — |
| ZLAB | Zai Lab Ltd | $2.91B | $23.53 | — |
| RCUS | Arcus Biosciences, Inc. | $2.36B | $16.39 | — |
News headlines (Yahoo Finance, 1h cache)
Norwest Announces $4 Billion Global, Multi-Stage Fund
2026-11-12 11:00 · Yahoo
MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
2026-11-09 21:01 · Yahoo
MBX Biosciences to Participate in Upcoming November Investor Conferences
2026-10-13 12:00 · Yahoo
Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?
2026-10-10 04:19 · Yahoo
MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%
2026-10-10 00:18 · Yahoo
MBX Biosciences to Participate in Upcoming Investor Conferences
2026-09-09 12:00 · Yahoo
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
2026-08-27 12:00 · Yahoo
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-06 12:00 · Yahoo
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
2026-07-13 20:15 · Yahoo
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
2026-06-12 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.